1 results match your criteria: "Mount Sinai School of Medicine and Memorial Sloan-Kettering Cancer Center[Affiliation]"
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.
J Clin Oncol
May 2002
Division of Medical Oncology, Mount Sinai School of Medicine and Memorial Sloan-Kettering Cancer Center, Box 1129, One Gustave L. Levy Place, New York, NY 10029, USA.
Purpose: Patients with high-risk myelodysplastic syndrome (MDS) have high mortality from bone marrow failure or transformation to acute leukemia. Supportive care is standard therapy. We previously reported that azacitidine (Aza C) was active in patients with high-risk MDS.
View Article and Find Full Text PDF